We're all set for a new experience. To visit the old Ventura website, click here.
Ventura Wealth Clients Login here

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open4,868
High4,923
Low4,811
Prev. Close4,862.5
Avg. Traded Price4,848.5
Volume1,81,782

MARKET DEPTH

info2
Total bid49.00
Total ask0.00
OrdersQtyBid
3494862.5
000
000
000
000
AskQtyOrders
000
000
000
000
000

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

4,811.0011 hours ago
4,923.0013 hours ago
arrow

LOWER/UPPER CIRCUITS

4,359.50
5,327.50
arrow
Alkem Laboratories Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 3.7%, in the last year to ₹13,458.26 Cr. Its sector's average revenue growth for the last fiscal year was 10.86%.
noteAnnual Net Profit,rose 20.59% in the last year to ₹2,165.48 Cr. Its sector's average net profit growth for the last fiscal year was 38.65%.
notePrice to Earning Ratio,is 26.74, lower than its sector PE ratio of 41.43.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 23.06%
Net profit growth 5Y CAGR : 18.55%

STOCK RETURNS

info
Versus Nifty 50
1 w
-5.09%
vs
-0.85%
1 mth
-1.75%
vs
+0.33%
3 mth
+8.27%
vs
+11.14%
6 mth
-11.92%
vs
+0.31%
1 yr
+6.12%
vs
+12.15%
3 yr
+61.15%
vs
+47.99%
5 yr
+104.36%
vs
+144.71%
Alkem Laboratories Limited is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments. The Company is a leading player in the acute therapeutic segment and a fast-growing player in the chronic therapeutic segment. India operations are underpinned by a robust sales and distribution network and extensive brand building and marketing efforts. The Company’s International business, built on a strong platform of a large and growing product pipeline, is a core part of its growth. These products are distributed through the Company’s own sales and commercial infrastructure.
personal

Grow your wealth with more research recommendations

+91